Replies to post #681 on Versartis, Inc. (VSAR)

[naturalborninvestor]

There are several more options, including resubmission at a higher dosage or buying revenues in an adjacent field. But a merger or acquisition is the most likely outcome. The drug certainly has value. Insiders had not put up in excess of $2 million through open market purchases if they expected this to just go out of business.

[longx]

By hiring Cowen, they're definitely working hard in getting the company sold given the possibility of Somavaratan to be optimized (w.r.t. dosage/frequent-usge) to meet all targets. Closing down shop, distributing the cash is the last option and they're NOT going to let it happen.